Bayer’s Twin Pressures: Supreme Court Ruling Looms as Trade Probe Targets Pharma Margins
Published on 06/24/2026 at 06:51 | Redaktion boerse-global.de
Bayer enters the final days of June 2026 caught between two potent forces. A Supreme Court decision in the Durnell case could either cap the glyphosate liability or leave the door open to fresh claims. Simultaneously, the U.S. Trade Representative has launched an investigation into German drug pricing that threatens the company’s most profitable market. The share, trading at €38.56, has rallied 45% over the past year, but that gain rests on fragile juridical and commercial foundations.
The highest court in the land is expected to rule at any point in the last week of June on whether federal pre-emption shields Bayer from state-level failure-to-warn lawsuits. If the justices rule that Environmental Protection Agency (EPA) approval of glyphosate trumps state tort claims, future litigation risks would be effectively neutralised. A loss, however, would leave the company exposed even after the planned $7.25 billion settlement, which is scheduled for a final hearing in Missouri on 9 July. A federal judge there has already given preliminary approval, and an attempt by critics to have the case moved to California was rejected earlier this month.
Against that backdrop, a different kind of Washington pressure is building. The office of Trade Representative Jamieson Greer has opened a formal investigation into whether U.S. patients are shouldering an unfair share of pharmaceutical research costs. The probe, citing American trade law, targets Germany’s strict pricing rules for innovative drugs. A public comment phase begins on 25 June, and a hearing will follow in September. While no tariffs have been imposed yet, the industry sees price concessions as a greater threat than duties alone—and Bayer’s pharma division is heavily reliant on the U.S. market, where drug prices can be three times higher than elsewhere.
Should investors sell immediately? Or is it worth buying Bayer?
The financial strain is already visible. Free cash flow in the first quarter of 2026 plunged to minus €2.32 billion, compared with minus €1.53 billion a year earlier, driven by roughly €2 billion in net payments for PCB and glyphosate litigation. Net financial debt climbed past €32 billion by the end of March, reversing much of the progress made in 2025, when the figure stood at €29.8 billion. For the full year, Bayer expects legal outflows of about €5 billion, and analysts project free cash flow could fall to as low as minus €2.5 billion.
Yet the company is not standing still. In June it completed the acquisition of Perfuse Therapeutics, securing full rights to the phase?II glaucoma and diabetic retinopathy implant PER?001. The upfront price was $300 million, with milestone payments that could bring the total to $2.45 billion. Meanwhile, regulators in Europe and the U.S. are reviewing the novel stroke prevention drug asundexian, which reduced stroke risk by 26% versus placebo in a phase?III trial, and the FDA approved Bayer’s contrast agent AMBELVIST in mid?June. These pipeline moves aim to fill the revenue gap left by Xarelto’s patent expiry and support management’s margin targets for 2030.
A fresh internal factor also comes into play. Dr. Judith Hartmann officially assumes the role of chief financial officer this month, tasked with stabilising net debt while billions flow out for legal settlements. Some investors continue to push for a structural review, including a potential spin?off of the consumer health unit, though no decision has been announced.
The immediate outlook hinges on the Supreme Court. A favourable ruling, combined with approval of the Missouri settlement, could clear the glyphosate cloud and push the stock toward its 52?week high of €49.93. A negative verdict, by contrast, would re?expose Bayer to endless litigation and likely trigger a retreat toward the year’s low of €25.09. Meanwhile, the trade investigation will remain a latent drag until September’s hearing, and any escalation in tariffs would compound the pressure on an already leveraged balance sheet. The next six weeks—from the Supreme Court ruling through the settlement hearing—will determine whether Bayer can finally turn a corner or finds itself trapped between a legal ceiling and a trade floor.
Ad
Bayer Stock: New Analysis - 24 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
